Ambitious Bio Adds University of Pittsburgh Chancellor Joan Gabel to Board

Ambitious CEO Elizabeth Hudson characterized the move as a strategic step in scaling the company’s efforts to build what she describes as a "Common Crawl for the living world." The startup, which exited stealth in June 2026, aims to create massive, foundational datasets for AI model training, proteomics, and disease research. By bringing in Gabel, the company gains a leader with a track record of driving patent output and managing high-stakes governance within top-tier academic health environments.

Gabel’s career includes leadership roles at the American Academy of Arts and Sciences and the U.S. Council on Competitiveness, where she has focused on national scientific standing. Her expertise in risk management is expected to guide Ambitious as it navigates the technical and ethical complexities of mapping the human proteome. Gabel noted that the infrastructure layer remains the most critical hurdle for integrating AI into clinical and research workflows, stating that she intends to help the company bridge the gap between raw biological material and actionable scientific discovery.